Investigations into an alternate approach to target mannose receptors on macrophages using 4-sulfated N-acetyl galactosamine more efficiently in comparison with mannose-decorated liposomes: An application in drug delivery

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue 4, 2012, Pages 468-477

  Singodia, Deepak ^a   Verma, Ashwni ^a   Verma, Rahul K ^a   Mishra, Prabhat Ranjan ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

4 sulfated N acetyl galactosamine; Liposomes; Macrophages; Mannose receptors

Indexed keywords

AMPHOTERICIN B; CATIONIC LIPOSOMES; ENHANCED UPTAKE; FLUORESCENCE INTENSITIES; FUTURE APPLICATIONS; IN-VIVO; INTRACELLULAR LOCALIZATION; MANNOSE RECEPTORS; MEAN PARTICLE SIZE; N-ACETYL GALACTOSAMINE; NON-TARGETED; RAW CELLS; SURFACE DECORATION; TIME POINTS;

CELL CULTURE; DRUG DELIVERY; GALACTOSAMINE; LIGANDS; LIPOSOMES; PHOSPHOLIPIDS; ZETA POTENTIAL;

MACROPHAGES;

4 SULFATE N ACETYLGALACTOSAMINE; AMPHOTERICIN B LIPID COMPLEX; LIPOSOME; MANNOSE; MANNOSE RECEPTOR; N ACETYLGALACTOSAMINE; UNCLASSIFIED DRUG;

ADSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL LINE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG TARGETING; FLOW CYTOMETRY; FLUORESCENCE SPECTROSCOPY; HUMAN; IN VITRO STUDY; LIPOSOMAL DELIVERY; MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; RAT; STATIC ELECTRICITY; ZETA POTENTIAL;

ACETYLGLUCOSAMINE; AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; CELL LINE; DRUG EVALUATION, PRECLINICAL; HUMANS; LECTINS, C-TYPE; LEISHMANIASIS; LIPOSOMES; MACROPHAGES; MANNOSE; MANNOSE-BINDING LECTINS; MICE; PARTICLE SIZE; RATS; RATS, WISTAR; RECEPTORS, CELL SURFACE;

EID: 84860234047     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.07.002     Document Type: Article

References (36)

1. Prakash J., Beljaars L., Harapanahalli A.K., Zeinstra-Smith M., de Jager-Krikken A., Hessing M., et al. Tumor-targeted intracellular delivery of anticancer drugs through the mannose-6-phosphate/insulin-like growth factor II receptor. Int J Cancer 2010, 126:1966-1981.
2. Nimje N., Agarwal A., Saraogi G.K., Lariya N., Rai G., Agrawal H., et al. Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting. J Drug Target 2009, 17:777-787.
3. Nahar M., Jain N.K. Preparation, characterization and evaluation of targeting potential of amphotericin B-loaded engineered PLGA nanoparticles. Pharm Res 2009, 26:2588-2598.
4. Yoo M.K., Park I.Y., Kim I.Y., Park I.K., Kwon J.S., Jeong H.J., et al. Superparamagnetic iron oxide nanoparticles coated with mannan for macrophage targeting. J Nanosci Nanotechnol 2008, 8:5196-5202.
5. Taylor M.E., Conary J.T., Lennartz M.R., Stahl P.D., Drickamer K. Primary structure of the mannose receptor contains multiple motifs resembling carbohydrate-recognition domains. J Biol Chem 1990, 265:12156-12162.
6. Ezekowitz R.A., Sastry K., Bailly P., Warner A. Molecular characterization of the human macrophage mannose receptor: demonstration of multiple carbohydrate recognition-like domains and phagocytosis of yeasts in Cos-1 cells. J Exp Med 1990, 172:1785-1794.
7. Taylor M.E., Drickamer K. Structural requirements for high affinity binding of complex ligands by the macrophage mannose receptor. J Biol Chem 1993, 268:399-404.
8. Taylor M.E., Bezouska K., Drickamer K. Contribution to ligand binding by multiple carbohydrate-recognition domains in the macrophage mannose receptor. J Biol Chem 1992, 267:1719-1726.
9. Fiete D.J., Beranek M.C., Baenziger J.U. A cysteine-rich domain of the "mannose" receptor mediates GalNAc-4-SO4 binding. Proc Natl Acad Sci U S A 1998, 95:2089-2093.
10. Leteux C., Chai W., Loveless R.W., Yuen C.T., Uhlin-Hansen L., Combarnous Y., et al. The cysteine-rich domain of the macrophage mannose receptor is a multispecific lectin that recognizes chondroitin sulfates A and B and sulfated oligosaccharides of blood group Lewis(a) and Lewis(x) types in addition to the sulfated N-glycans of lutropin. JExp Med 2000, 191:1117-1126.
11. Liu J., Teng L., Liu C., Hu L., Wang Y., Liu H., et al. Augmented inhibitory effect of superoxide dismutase on superoxide anion release from macrophages by chemical modification with polysaccharide and attenuation effects on radiation-induced inflammatory cytokine expression in vitro. J Drug Target 2009, 17:216-224.
12. Colonna C., Conti B., Genta I., Alpar O.H. Non-viral dried powders for respiratory gene delivery prepared by cationic and chitosan loaded liposomes. Int J Pharm 2008, 364:108-118.
13. Chen C.L., Wang Y.M., Liu C.F., Wang J.Y. The effect of water-soluble chitosan on macrophage activation and the attenuation of mite allergen-induced airway inflammation. Biomaterials 2008, 29:2173-2182.
14. Hammerling U., Westphal O. Synthesis and use of O-stearoyl polysaccharides in passive hemagglutination and hemolysis. Eur J Biochem 1967, 1:46-50.
15. Vyas S.P., Katare Y.K., Mishra V., Sihorkar V. Ligand directed macrophage targeting of amphotericin B loaded liposomes. Int J Pharm 2000, 210:1-14.
16. Duverger A., Jackson R.J., van Ginkel F.W., Fischer R., Tafaro A., Leppla S.H., et al. Bacillus anthracis Edema Toxin Acts as an Adjuvant for Mucosal Immune Responses to Nasally Administered Vaccine Antigens. J Immunol 2006, 176:1776-1783.
17. Seelagy M.M., Schwartz A.R., Russ D.B., King E.D., Wise R.A., Smith P.L. Reflex modulation of airflow dynamics through the upper airway. J Appl Physiol 1994, 76:2692-2700.
18. Seymour A.A., Sheldon J.H., Smith P.L., Asaad M., Rogers W.L. Potentiation of the renal responses to bradykinin by inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in anesthetized dogs. J Pharmacol Exp Ther 1994, 269:263-270.
19. van Etten E.W.M., Otte-Lambillion M., van Vianen W., Kate M.T.T., Bakker-Woudenberg I.A.J.M. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. J Antimicrob Chemother 1995, 35:509-519.
20. van Etten E.W.M., van den Heuvel-de Groot C., Bakker-Woudenberg I.A.J.M. Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment ofsystemic candidosis in immunocompetent and leucopenic mice. JAntimicrob Chemother 1993, 32:723-739.
21. Wang J.J., Sung K.C., Hu O.Y., Yeh C.H., Fang J.Y. Submicron lipid emulsion as a drug delivery system for nalbuphine and its prodrugs. JControl Release 2006, 115:140-149.
22. Pavia D.L., Lampman G.L., Kriz G.S. Infrared absorption process. Introduction to Spectroscopy: A guide for Students of Organic Chemistry 1979, 13-15. Cengage Learning, Philadelphia. G. Hoit, K.L. Rinehart, I.B. Weinstein (Eds.).
23. Shende P., Gaud R. Formulation and comparative characterization of chitosan, gelatin, and chitosan-gelatin-coated liposomes of CPT-11-HCl. Drug Dev Ind Pharm 2009, 35:612-618.
24. Wagner A., Platzgummer M., Kreismayr G., Quendler H., Stiegler G., Ferko B., et al. GMP production of liposomes-a new industrial approach. JLiposome Res 2006, 16:311-319.
25. Stano P., Bufali S., Pisano C., Bucci F., Barbarino M., Santaniello M., et al. Novel camptothecin analogue (gimatecan)-containing liposomes prepared by the ethanol injection method. J Liposome Res 2004, 14:87-109.
26. East L., Isacke C.M. The mannose receptor family. Biochim Biophys Acta 2002, 1572:364-386.
27. East L., Rushton S., Taylor M.E., Isacke C.M. Characterization of sugar binding by the mannose receptor family member, Endo180. J Biol Chem 2002, 277:50469-50475.
28. Dinges D.F., Kribbs N.B., Schwartz A.R., Smith P.L., Pack A.I. Objective measurement of nasal continuous positive airway pressure use: ethical considerations. Am J Respir Crit Care Med 1994, 149:291-292.
29. Weis W.I., Drickamer K., Hendrickson W.A. Structure of a C-type mannose-binding protein complexed with an oligosaccharide. Nature 1992, 360:127-134.
30. Weis W.I., Drickamer K. Structural basis of lectin-carbohydrate recognition. Annu Rev Biochem 1996, 65:441-473.
31. Fiete D., Beranek M.C., Baenziger J.U. The macrophage/endothelial cell mannose receptor cDNA encodes a protein that binds oligosaccharides terminating with SO4-4-GalNAcbeta1,4GlcNAcbeta or Man at independent sites. Proc Natl Acad Sci U S A 1997, 94:11256-11261.
32. Mitra M., Mandal A.K., Chatterjee T.K., Das N. Targeting of mannosylated liposome incorporated benzyl derivative of Penicillium nigricans derived compound MT81 to reticuloendothelial systems for the treatment of visceral leishmaniasis. J Drug Target 2005, 13:285-293.
33. Medda S., Jaisankar P., Manna R.K., Pal B., Giri V.S., Basu M.K. Phospholipid microspheres: a novel delivery mode for targeting antileishmanial agent in experimental leishmaniasis. J Drug Target 2003, 11:123-128.
34. Datta N., Mukherjee S., Das L., Das P.K. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation. Eur J Immunol 2003, 33:1508-1518.
35. Martinez-Pomares L., Crocker P.R., Da Silva R., Holmes N., Colominas C., Rudd P., et al. Cell-specific glycoforms of sialoadhesin and CD45 are counter-receptors for the cysteine-rich domain of the mannose receptor. JBiol Chem 1999, 274:35211-35218.
36. Fiete D., Baenziger J.U. Isolation of the SO4-4-GalNAcbeta1,4GlcNAcbeta1,2Manalpha-specific receptor from rat liver. J Biol Chem 1997, 272:14629-14637.